Skip to main content

Table 2 Non-population-based retrospective cohort studies reporting prognosis of patients with de novo post-transplant melanoma

From: Systematic review of melanoma incidence and prognosis in solid organ transplant recipients

First author (publication year)

Location

Transplant data source

Number of cases of melanoma

Staging data (number of patients with data)

Outcomes

Brewer[20]a

United States

Mayo Clinic databases, OPTN, IPITTR

638

AJCC pathologic stage (67 tumors)

Worse 3-year, cause-specific survival for Breslow 1.51 to 3.0 mm and Clark level III or IV in transplant recipients versus controls.

    

Breslow depth (123)

 

Frankenthaler[21]

United States

BIDMC Cutaneous Oncology Program database

4 (renal transplant)

15 (autoimmune disease)

AJCC stage (19)

Similar relapse rates but worse overall survival in immunosuppressed group versus controls.

     

Similar stage distribution at diagnosis compared to general melanoma database.

Matin[26]

Europe

SCOPE, AJCC

89

Breslow depth (83)

Worse overall survival for Breslow >2 mm in transplant patients versus controls (HR 11.5, 95% CI 3.6 to 36.8), but not found for Breslow ≤2 mm (HR 1.5, 95% CI 0.31 to 6.9).

Clark level (82)

Ulceration (79)

     

14 patients with metastasis.

Le Mire[22]

United Kingdom

Oxford renal transplant unit

10

Breslow depth (10)

Clark level (10)

Ulceration (10)

1 patient died from metastatic melanoma (Breslow 4.5 mm).

     

No recurrence in other cases (all <1 mm).

Veness[23]

Australia

St Vincent Hospital, Sydney

8

Regional lymph node status (2)

4 deaths from metastasis.

Lévêque[24]

France

9 centers

17

Breslow depth (16)

Clark level (16)

Ulceration (16)

4 deaths from metastasis

  1. aOverlap with three prior studies[25, 27, 28].
  2. AJCC, American Joint Committee on Cancer; BIDMC, Beth Israel Deaconess Medical Center; CI, confidence interval; HR, hazard ratio; IPITTR, Israel Penn International Transplant Tumor Registry (previously Cincinnati transplant tumor registry); OPTN, Organ Procurement and Transplantation Network; SCOPE, Skin Care in Organ Transplant Patients, Europe.